ArticleCEN case reports2026
Measurement of complement proteins may aid interpretation of pathophysiology in kidney transplant recipients with atypical hemolytic uremic syndrome.
Article in CEN case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
A 53-year-old woman with kidney failure and low-titer donor-specific antibody underwent a living-unrelated donor kidney transplant. Presentation of severe thrombotic microangiopathy (TMA) resulted in early graft loss at day 8 post-transplant and initiation of hemodialysis. Thorough examination of the medical data revealed the patient to have had atypical hemolytic uremic syndrome (aHUS). Hemolytic anemia persisted for several months, even after complete embolization of the kidney graft. The patient subsequently received prophylactic eculizumab treatment and underwent a successful second transplant from a familial donor. Withdrawal of eculizumab resulted in development of TMA in the second graft, while reintroduction of eculizumab reversed the TMA. We examined complement-related profiles over time, and serial measurement of factors such as factor Ba, soluble C5b-9, and C3, and of total complement activity (CH50), clearly reflected the underlying pathophysiological condition and treatment status of the patient before, during, and after transplant. Longitudinal observation of complement protein levels may therefore aid in identifying candidates for kidney transplant who are at risk of aHUS, and monitoring patient status during transplant and follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.